Chugai Pharmaceutical Co. Ltd., of Tokyo, said it is expanding Chugai Pharmabody Research Pte. Ltd. (CPR), its research subsidiary in Singapore, to further improve drug discovery capabilities of the Chugai Group, in which the operation period of CPR is to be extended for another five years with an investment of SG$282 million (US$206.88 million) from 2022 to 2026. Read More
Acorda Therapeutics Inc., of Ardsley, N.Y., disclosed in an SEC filing that the U.S. Court of Appeals for the Federal Circuit denied per curiam the company's motion for an injunction pending a decision in its appeal of a U.S. District Court decision in patent litigation with certain generic drug manufacturers. Read More
LONDON – Healx Ltd. raised $10 million in a series A funding, allowing it to scale its drug repurposing platform and provide a systematic and standardized method for finding treatments for any rare disease. Read More
Researchers from the University of Toronto's Sunnybrook Health Sciences Centre have demonstrated that they could safely and reversibly open the blood-brain barrier (BBB) by using MRI-guided ultrasound combined with microbubbles. Read More
DUBLIN – With Opdivo (nivolumab) about to cede leadership in the PD-1 inhibitor market to longtime rival Keytruda (pembrolizumab) today, the EMA's Committee on Human Medicinal Products (CHMP) did not pick a good time to refuse Bristol-Myers Squibb Co. an application for Opdivo plus low-dose Yervoy (ipilimumab) in first-line renal cell carcinoma (RCC). Read More
As it did two weeks ago when it first encountered a tafenoquine drug, the FDA's Antimicrobial Drugs Advisory Committee gave 60 Degrees Pharmaceuticals LLC's Arakoda two thumbs up Thursday. Read More
A better-than-expected second-quarter profit at Celgene Corp. and news of a planned exit by Gilead Sciences Inc. CEO John Milligan led a parade of earnings news, carried by a drumbeat of estimate-beating results at companies including Alexion Pharmaceuticals Inc., Vertex Pharmaceuticals Inc. and Alkermes plc as demand for key products at the companies grew. Pricing pressures remained a specter, gaining at least some outward acknowledgment at Celgene, while tariff troubles dogging other sectors remained, blissfully for biopharma investors, at bay. Amgen Inc. also reported earnings following the market's close. Read More
Biogen Inc. and Eisai Co. Ltd. raised the curtain on phase II data from Study 201 in early Alzheimer's disease (AD) with anti-amyloid beta protofibril antibody BAN-2401, offering promise at last against the scourge that has foiled so many candidates. Read More
